EOM 1352: Fri 7 June 2024, 11:36

Current Edition

Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
Europe

Regorafenib to be tested in brain cancer patients in multi-arm cooperation trial

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in t...
Continue Reading →
Europe

FDA lifts hold on AbbVie multiple myeloma study

The Food and Drug Administration has lifted a clinical hold on one multiple myeloma trial for AbbVie's Venclexta after making several changes to the study protocols,...
Continue Reading →
news

ImmusanT cans phase 2 celiac trial after interim efficacy review

ImmusanT saw celiac disease as a good proving ground for its approach. (Pixabay) ImmusanT has stopped a phase 2 trial of its lead candidate in celiac disease aft...
Continue Reading →
news

Agilent receives FDA approval for companion diagnostic assay

The assay is now approved as an aid in identifying patients with head and neck squamous cell carcinoma image credit- istock.com Agilent Technologies Inc. has a...
Continue Reading →
Europe

Varian completes acquisition of Cancer Treatment Services International

This transaction will accelerate identification of unmet clinical and operational needs to facilitate advances in technology and services Varian has announced that...
Continue Reading →
news

Biotechs dive deeper into targeted cancer research, despite costs

CHICAGO — An AstraZeneca cancer drug works best in people with an uncommon mutation. For a recent study evaluating whether the drug offered benefits to pancreatic...
Continue Reading →
Europe

Experimental drug delays Type 1 diabetes in research first

An experimental biologic drug appeared to substantially delay the development of Type 1 diabetes in people at high risk for the chronic condition, surprising results...
Continue Reading →
news

ADA: J&J’s struggling Invokana slashes heart, kidney risks in latest trial win

J&J is awaiting a CKD approval for Invokana after receiving a priority review from the FDA. (Johnson & Johnson) SAN FRANCISCO—Johnson & Johnson and i...
Continue Reading →
Europe

Roche touts phase 2 Gazyva data in lupus patients with a potentially fatal kidney complication

Roche cancer drug Gazyva met its endpoint in a phase 2 lupus nephritis study, the company said. (Roche) One brand-new FDA approval and one trial win for its bloo...
Continue Reading →
news

NASH trial miss halves CymaBay’s market value

An experimental drug from CymaBay Therapeutics missed the primary endpoint of a mid-stage NASH trial, cutting the stock price of the California biotech in half Tuesd...
Continue Reading →
Catalyst: 12th January 2026
Quotient